RARE ULTRAGENYX PHARMACEUTICAL INC Earnings Reports 8-K Filing 2023 - Earnings Reports Ultragenyx Pharmaceutical Inc. issued a press release announcing preliminary unaudited fiscal year 2022 total revenue, revenue for Crysvita and Dojolvi, cash and investments at 2022 fiscal year end, total 2023 revenue guidance, and expected 2023 net cash used in operations.Get access to all SEC 8-K filings of the ULTRAGENYX PHARMACEUTICAL INC